by Maria Zannes | Oct 15, 2015 | Events, Press Releases
OCTOBER 15, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, presented its breakthrough technology for the detection and diagnosis of early-stage lung cancer today at McDermott Will & Emery’s 2015...
by Maria Zannes | Oct 7, 2015 | Press Releases
OCTOBER 7, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, will seat two new members on its Board of Directors at the third-quarter meeting Oct. 26, 2015. Company President and Chief Executive Officer Maria Zannes...
by Maria Zannes | Sep 30, 2015 | Press Releases
SEPTEMBER 30, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, today announced the renewal of its research collaboration with The University of Texas Health Science Center at San Antonio to optimize its patented CyPath®...
by Maria Zannes | Sep 23, 2015 | Press Releases
SEPTEMBER 23, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that results from a 128-patient proof-of-concept clinical study for its non-invasive and quantitative assay for early-stage lung cancer were...
